Literature DB >> 24105780

Is early surveillance with CT scan necessary in patients with stage II/III colorectal cancer: a retrospective study.

Guo-Chen Liu1, Jing-Hua Tang, Shu-Juan Wen, Hua-Xiang Cao, Xin An, Pei-Qiang Cai, Ling-Heng Kong, Jun-Zhong Lin, Li-Ren Li, Zhi-Zhong Pan, Pei-Rong Ding.   

Abstract

BACKGROUND AND OBJECTIVES: This analysis aims to evaluate the value of early surveillance within 6 months after resection for stage II/III colorectal cancer (CRC).
METHODS: Patients with stage II/III CRC who received surgery with curative intent for CRC were included. CT scans of the chest, abdomen, and pelvis performed within 6 months after surgery were evaluated.
RESULTS: Among 150 patients included in the study, 10 patients (1 occurred in stage II disease and 9 occurred in stage III) were diagnosed as recurrence within 6 months after surgery. The proportion of patients diagnosed as recurrence was significantly higher in stage III disease than in stage II disease (P = 0.01). The likelihood of recurrence within 6 months was associated with the extent of lymph node metastases (r = 0.205, P = 0.012). Three patients with recurrent disease underwent salvage resection with curative intent.
CONCLUSIONS: Early surveillance with CT scan within 6 months after curative resection may not be necessary for stage II disease. Although, the strategy may be helpful for stage III disease considering the high incidence of salvage surgery for recurrence disease, the early detection of recurrence could not be translated into survival benefit.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CT scan; colorectal cancer; early surveillance

Mesh:

Year:  2013        PMID: 24105780     DOI: 10.1002/jso.23432

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  1 in total

1.  The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Guo-Chen Liu; Xu Zhang; E Xie; Xin An; Pei-Qiang Cai; Ying Zhu; Jing-Hua Tang; Ling-Heng Kong; Jun-Zhong Lin; Zhi-Zhong Pan; Pei-Rong Ding
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.